Pre-Made Valanafusp Alfa Biosimilar, Fusion Protein targeting INSR fused with human IDUA (iduronidase, alpha-L-) (1:2): Recombinant therapeutic protein targeting CD220/HHF5 for drug discovery and mechanism of action (MOA) research

Pre-Made Valanafusp Alfa Biosimilar, Fusion Protein targeting INSR fused with human IDUA (iduronidase, alpha-L-) (1:2): Recombinant therapeutic protein targeting CD220/HHF5 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Valanafusp alpha, is a blood¨Cbrain barrier (BBB)-penetrating IgG- ¦Á-L-iduronidase fusion protein, where the IgG domain is a monoclonal antibody (MAb) that targets the human insulin receptor (HIR). Mucopolysaccharidosis type I (MPSI) is caused by mutations in the gene encoding the a-L-iduronidase (IDUA) lysosomal enzyme and the majority of MPSI patients have severe central nervous system (CNS) involvement. The HIRMAb domain of valanafusp alpha binds to the endogenous insulin receptor on the human BBB to trigger receptor-mediated transport across the BBB, and acts as a molecular Trojan horse to ferry the fused IDUA into the brain of patients with MPSI.